Litigation Details for Acuitas Therapeutics Inc. v. Genevant Sciences GmbH (S.D.N.Y. 2022)
✉ Email this page to a colleague
Acuitas Therapeutics Inc. v. Genevant Sciences GmbH (S.D.N.Y. 2022)
| Docket | ⤷ Try a Trial | Date Filed | 2022-03-18 |
| Court | District Court, S.D. New York | Date Terminated | 2023-08-07 |
| Cause | 28:2201dj Declaratory Judgment | Assigned To | Edgardo Ramos |
| Jury Demand | None | Referred To | |
| Patents | 8,058,069; 8,492,359; 8,822,668; 9,364,435 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Acuitas Therapeutics Inc. v. Genevant Sciences GmbH
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Acuitas Therapeutics Inc. v. Genevant Sciences GmbH (S.D.N.Y. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-03-18 | 1 | Complaint | Therapeutics Inc.. (Attachments: # 1 Exhibit A-US 8,058,069, # 2 Exhibit B-US 8,492,359, # 3 Exhibit C-US …2022 7 August 2023 1:22-cv-02229 830 Patent None District Court, S.D. New York | External link to document |
| 2022-09-06 | 42 | Amended Complaint | Exhibit A-US Patent No. 8,058,069, # 3 Exhibit B-US Patent No. 8,492,359, # 4 Exhibit C-US Patent No. 8,822,668…Exhibit D-US Patent No. 9,006,417, # 6 Exhibit E-US Patent No. 9,364,435, # 7 Exhibit F-US Patent No. 9,404,127…Exhibit G-US Patent No. 9,504,651, # 9 Exhibit H-US Patent No. 9,518,272, # 10 Exhibit I-US Patent No. 11,141,378…2022 7 August 2023 1:22-cv-02229 830 Patent None District Court, S.D. New York | External link to document |
| 2022-10-04 | 44 | Memorandum of Law in Support of Motion | See, e.g., Dkt. 1-1 (U.S. Patent No. 8,058,069, claim 1). All the patents require both a nucleic acid…for two patents, the ’502 patent and the ’402 patent mentioned above. Addressing each patent in turn,…multiple patents. A product infringing the patentee’s patent might therefore also apply the patents of third…claim of nine patents owned by Arbutus and licensed to Genevant (“Defendants’ Patents”) and that Defendants…2018, BNT licensed Defendants’ Patents from Genevant, among other patents, in connection with BNT’s development | External link to document |
| 2023-08-01 | 78 | Exhibit A - NJ Counterclaims | vaccine may infringe Arbutus patents, including at least U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668… Application issued as U.S. Pat. No. 8,058,069 (the “’069 Patent”) on November 15, 2011. …Office issued the ’651 Patent, ’359 Patent, ’378 Patent, ’320 Patent, and ’098 Patent, but deny that the …“’708 Patent”), 8,329,070 (the “’070 Patent”), and 9,492,386 (the “’386 Patent”). Each patent claims…manufacturing them. Among those patents are the Asserted Patents: a. U.S. Patent No. 9,504,651, “Lipid | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
